Having demonstrated the efficacy of ts SeV in delivering Cas9 and a gRNA to CD34+ HSPCs, we extended our investigation to its potential in the context of primary CD14+ monocytes for the purpose of inhibiting HIV infection. Here, CD34 is linked to HIV infectious disease.